Johnson & Johnson gives upbeat view of pharma and consumer businesses

US health care major Johnson & Johnson highlighted its pharmaceutical and consumer businesses at a meeting with financial analysts earlier this month, when it described its broadly-based health care business as strong and poised for continued growth in the coming years. Senior leaders from the company outlined the current pharmaceutical and consumer business portfolios and growth strategies that will enable the J&J group to capitalize on growing demand in the area of human health and well-being. They aimed to allay investors fears about being able to develop new drugs quickly enough to compensate for aging blockbusters.

J&J's vice chairman, Christine Poon, underscored how the company believes it is uniquely positioned with its breadth of businesses and flexible operating model to outperform its competitors in a $4,000.0 billion global market for health solutions."Being broadly based is a cornerstone of our success and will amplify our growth going forward," Ms Poon said in her opening remarks.

Ms Poon discussed several early-stage ventures that she said illustrate how the company cultivates innovation across its broad base of businesses. The initiatives are based on collaborative work that capitalizes on capabilities and resources across the company's three businesses segments - Consumer, Pharmaceuticals and Medical Devices and Diagnostics.